



## ASX ANNOUNCEMENT

### CEO Transition and Interim Leadership Update

**29 JANUARY 2026**

**Melbourne, Australia** – Vitura Health Limited (ASX: VIT) (**Vitura and Company**) today announced that Chief Executive Officer, Geoff Cockerill, had ceased in his role, effective from the close of business on 28 January 2026.

The Board thanks Mr Cockerill for his contribution to the Company.

As Vitura continues its focus on delivering improved financial and operational performance, the Board determined that new leadership was required to accelerate execution of the Company's strategic priorities.

#### **Interim Leadership Arrangements**

Effective immediately, Ryan Tattle, Chief Revenue Officer, has assumed expanded leadership responsibility for Vitura's day-to-day management until a new CEO is appointed. All Executive Leadership Team members will report directly to Mr Tattle during this interim period.

Mr Tattle brings extensive commercial experience and a deep understanding of Vitura's operations and growth strategy, having played a key role in the early stages of the Company's strategic reset and performance improvement initiatives.

To support the executive team, Shane Tanner, currently a Non-Executive Director, will step into an Interim Executive Director role. Mr Tanner will work closely with Mr Tattle to help execute the Company's operational and performance improvement initiatives. Please refer to Appendix A (below) for details of Mr Tanner's remuneration and employment arrangements in relation to his interim appointment.

#### **Chief Executive Officer Search**

The Board has commenced a prioritised search for a new Chief Executive Officer. The process to appoint an experienced, execution-focused leader to successfully deliver the next phase of Vitura's transformation is advanced.

#### **Updated Commencement of Chief Financial Officer**

Vitura is pleased to confirm its incoming CFO Andrew Cook will be commencing with the business on 9 February 2026, ahead of expectations. Andrew has over 20 years' international experience in senior finance roles across diverse industries with a strong track record of delivery in large complex organisations. He has held senior positions in leading businesses including Energy Queensland, Origin Energy, SABMiller and most recently as Chief Financial Officer and Company Secretary of AnteoTech Limited.

Vitura Chair Robert Iervasi said: "The Company's strategic priorities remained unchanged as it continues to focus on operational excellence, financial discipline, and strengthening its position as a trusted provider in the healthcare services sector."

For personal use only

## APPENDIX A

The material terms of Mr Tanner's employment as Interim Executive Director are summarised below:

Key Terms	Details
Appointment and Commencement Date	Mr Tanner was appointed as Interim Executive Director of the Company, commencing on 29 January 2026.
Term	Mr Tanner's appointment as Interim Executive Director will continue until 30 April 2026, with the option to extend until 30 June 2026 or until a new CEO is appointed (as agreed in writing between Mr Tanner and the Board).
Fee	A fee of \$100,000 per annum will be paid on a pro-rata basis through the period of appointment. This fee is exclusive of Mr Tanner's existing Non-Executive Board fees.
Termination	Either party may terminate the engagement by providing 30 days' written notice.

### About Vitura Health Limited (ASX: VIT)

- [www.vitura.com.au](http://www.vitura.com.au)

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- [www.burleighheads cannabis.com](http://www.burleighheads cannabis.com)

Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes roughly 600 therapeutic product and device SKUs within Australia from roughly 70 international and domestic brands.

- [www.canview.com.au](http://www.canview.com.au)

Canview is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the roughly 4,700 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- [www.doctorsondemand.com.au](http://www.doctorsondemand.com.au)

The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health and medicated weight loss.

- [www.cortexa.com.au](http://www.cortexa.com.au)

The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.

- [www.candor.com.au](http://www.candor.com.au)

The Company owns Candor Medical that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis and other speciality products and services.

- [www.releaf.com.au](http://www.releaf.com.au)

The Company owns a 50% equity interest in Flora Holdings Pty Ltd, a joint venture that owns and operates a series of medicinal cannabis clinics operating under the Releaf brand.

- [www.cdaclinics.com.au](http://www.cdaclinics.com.au)

The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

- [www.cannadoc.com.au](http://www.cannadoc.com.au)

The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

**Authorised by** - The Board of Vitura Health Limited.

**Contact**

**Vitura Health Limited**

Robert Iervasi  
Chair  
1300 799 491  
[info@vitura.com.au](mailto:info@vitura.com.au)

**Media enquiries**

Dieter Lehmann  
Nominis Communications  
+61 427 672 995  
[dieter@nominis.me](mailto:dieter@nominis.me)

**Forward-looking statements**

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.